Gene Therapy for Thalassemia Approved in Europe
June 3, 2019 – Gene therapy procedure for thalassemia has been approved in Europe. ZYNTEGLO™ is the first gene therapy approved – in Europe – for the treatment of transfusion-dependent beta-thalassemia: bluebird bio has received conditional marketing authorization from the European Commission for ZYNTEGLO™. ZYNTEGLO™ is a gene therapy for the treatment of patients 12 and older with transfusion-dependent beta-thalassemia who do not have a B0/B0 genotype, for whom hematopoietic stem cell transplantation is appropriate but for whom an HLA-matched donor is not available.
Further information is available in the press release at: https://www.businesswire.com/news/home/20190603005497/en/